NCT03984318View on ClinicalTrials.gov

Predictive Markers of Immune-related Adverse Events in Patients Treated With Immune Stimulatory Drugs

NAActive, not recruitingINTERVENTIONAL
Enrollment

1,240

Participants

Timeline

Start Date

December 12, 2018

Primary Completion Date

December 11, 2026

Study Completion Date

December 11, 2028

Conditions
Cancer
Interventions
PROCEDURE

Blood sample

Blood (plasma+serum+PBMC) collection before the start of immunotherapy, at week 6 and upon grade ≥2 irAE.

Trial Locations (5)

92350

Hôpital Marie Lannelongue, Le Plessis-Robinson

94270

Hôpital Bicêtre, Le Kremlin-Bicêtre

94550

Gustave Roussy, Chevilly-Larue

94800

Hôpital Paul Brousse, Villejuif

94805

Gustave Roussy, Villejuif

All Listed Sponsors
lead

Gustave Roussy, Cancer Campus, Grand Paris

OTHER

NCT03984318 - Predictive Markers of Immune-related Adverse Events in Patients Treated With Immune Stimulatory Drugs | Biotech Hunter | Biotech Hunter